Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.

Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1391-8.

PMID:
23138167
2.

[Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].

Song Q, Li X, Li B.

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015 Jan;29(1):67-75. Review. Chinese.

PMID:
25966559
3.

Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Greenhalgh J, Bagust A, Boland A, Fleeman N, McLeod C, Dundar Y, Proudlove C, Shaw R.

Health Technol Assess. 2009 Oct;13 Suppl 3:49-54. doi: 10.3310/hta13suppl3/08. Review.

4.

The role of cetuximab in the treatment of squamous cell cancer of the head and neck.

Burtness B.

Expert Opin Biol Ther. 2005 Aug;5(8):1085-93. Review.

PMID:
16050785
5.

Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis.

Abdel-Rahman O, Fouad M.

Crit Rev Oncol Hematol. 2015 Feb;93(2):127-35. doi: 10.1016/j.critrevonc.2014.07.005. Epub 2014 Aug 12. Review.

PMID:
25139841

Supplemental Content

Write to the Help Desk